You are here: Home » News » Market » Text

Mitsubishi Tanabe Shows News Dosage to Antipsychotic Agent

放大字体  缩小字体 Release date:2016-11-30  Views:62
Core Tip: Mitsubishi Tanabe Pharma is introducing Depas tablets 0.25mg, a new dosage to be added to the series of tranquilizer being currently available under the brand names Depas tablets 0

Mitsubishi Tanabe Pharma is introducing Depas tablets 0.25mg, a new dosage to be added to the series of tranquilizer being currently available under the brand names Depas tablets 0.5mg, Depas tablets 1gm and Depas fine granules 1%, in Japan.

The antipsychotic agent exhibits pharmacological properties, potent anxiolytic effect, sedative/hypotonic effect and relief from myotonia.

The drug is indicated for psychosomatic disease, neurosis, low back pain, cervical spondylosis and tension headache, depression and sleep disorder.

Etizolam (marketed under the brand name Etilaam, Etizola, Sedekopan, Pasaden or Depas) is a thienodiazepine drug which is a benzodiazepine analog. The etizolam molecule differs from a benzodiazepine in that the benzene ring has been replaced by a thiophene ring.

Mitsubishi Tanabe Pharma is a Japanese pharmaceuticals company, a subsidiary of Mitsubishi Chemical Holdings Corporation.

 

 
 
[ NewsSearch ]  [ Add to Favorites ]  [ Tell a friend ]  [ Print ]  [ Close the window ]

 
Total0bar [View All]  Related Comments

 
Recommended Graphic
RecommendNews
Click Ranking